IL1A encodes interleukin-1 alpha, a pleiotropic pro-inflammatory cytokine and founding member of the interleukin-1 family. Located on chromosome 2q14.1, IL1A is expressed across multiple tissues including the brain, where it serves as a master regulator of neuroinflammatory responses. IL1A plays a critical role in the neuroinflammation that characterizes Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other neurodegenerative conditions.
Unlike its close relative IL1B, which is secreted as a mature active protein after inflammasome-mediated cleavage, IL1A is biologically active in both its pro-form (31 kDa) and mature form (17 kDa). This allows IL1A to function both intracellularly and extracellularly, contributing to both autocrine and paracrine inflammatory signaling.
IL1A is a potent pleiotropic cytokine that initiates and amplifies inflammatory responses. Unlike IL1B which is secreted as a mature protein, IL1A is active in both its pro-form and mature form. The cytokine functions include:
- Autocrine activation: IL1A acts on the same cell that produces it, creating a self-amplifying inflammatory loop
- Paracrine signaling: IL1A from microglia and astrocytes activates neighboring cells including neurons, other glia, and endothelial cells
- Systemic effects: IL1A can access the hypothalamus via the organum vasculosum of the lamina terminalis to induce fever and sickness behavior
- Intracellular signaling: Full-length pro-IL1A can signal from within the nucleus, where it may regulate gene expression independently of receptor engagement
IL1A signals through multiple receptor interactions:
- IL1R1 (signaling): The functional signaling receptor, requires the accessory protein IL1RAP for signal transduction. Binding triggers MyD88-dependent signaling cascade leading to NF-κB and MAPK activation
- IL1R2 (decoy): A soluble or membrane-bound receptor that lacks a TIR domain and cannot signal. Acts as a natural inhibitor by sequestering IL1A and IL1B
- IL-1RA (antagonist): The IL-1 receptor antagonist (anakinra) competes for IL1R1 binding without triggering signaling
| Cell Type |
Expression Pattern |
Key Role |
| Microglia |
Constitutive low, dramatically upregulated by injury/pathology |
Primary IL1A source in neurodegeneration |
| Astrocytes |
Moderate constitutive, stress-induced upregulation |
Propagate neuroinflammation through gap junction communication |
| Neurons |
Low constitutive, pathological induction |
Contribute to neuronal dysfunction through autocrine signaling |
| Oligodendrocytes |
Stress-responsive |
Vulnerability to IL1A-mediated damage |
| Endothelial cells |
Low, upregulated in inflammation |
Blood-brain barrier dysfunction and leukocyte recruitment |
Under normal conditions, IL1A is tightly regulated in the brain:
- Low baseline expression in microglia maintains surveillance state
- Neuronal IL1A expression is nearly absent but induced by injury
- Astrocyte IL1A production is triggered by pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs)
- Constitutive IL1R2 expression in healthy brain limits accidental IL1A signaling
IL1A is strongly implicated in AD pathogenesis through multiple mechanisms:
- Genetic susceptibility: IL1A promoter polymorphisms (-889C/T, rs1800587) associated with increased AD risk in meta-analyses of over 10,000 subjects
- Inflammasome activation: IL1A activates the NLRP3 inflammasome in microglia, driving chronic neuroinflammation and IL1B release
- Amyloid interaction: IL1A enhances amyloid precursor protein (APP) processing and Aβ production through NF-κB-mediated BACE1 upregulation
- Tau pathology: IL1A drives tau hyperphosphorylation through GSK3β and CDK5 activation; IL1A levels correlate with Braak staging
- Synaptic dysfunction: IL1A impairs long-term potentiation (LTP) and synaptic plasticity through NMDA receptor modulation
- Brain region vulnerability: IL1A is highest in hippocampus and entorhinal cortex, matching early AD pathology
- Therapeutic relevance: IL-1 receptor blockade reduces AD-like pathology in 3xTg and 5xFAD mouse models
IL1A drives neuroinflammation and dopaminergic degeneration in PD:
- Elevated in PD brain: IL1A mRNA and protein are increased 3-5 fold in the substantia nigra pars compacta of PD patients
- CSF biomarkers: IL1A is elevated in PD CSF and correlates with disease severity (UPDRS-III scores)
- Dopaminergic toxicity: IL1A synergizes with MPTP, 6-OHDA, and alpha-synuclein to kill dopaminergic neurons
- Microglial activation: IL1A is a key trigger of the pro-inflammatory M1 microglial phenotype
- αSyn propagation: IL1A-induced neuroinflammation may facilitate the cell-to-cell spreading of alpha-synuclein pathology
- Genetic evidence: IL1A promoter variants modify PD age at onset in GWAS studies
IL1A contributes to demyelination and disease progression in MS:
- Blood-brain barrier disruption: IL1A increases BBB permeability through VEGF and MMP-9 upregulation, allowing immune cell infiltration
- Oligodendrocyte toxicity: IL1A directly damages oligodendrocytes through caspase-1-dependent apoptosis
- T-cell activation: IL1A promotes Th17 differentiation and autoimmune responses in the CNS
- EAE models: IL1A-deficient mice are resistant to experimental autoimmune encephalomyelitis (EAE)
IL1A is elevated in ALS CSF and contributes to motor neuron vulnerability:
- CSF IL1A levels are significantly elevated in ALS patients compared to controls
- Genetic variants in the IL1A/IL1B pathway modify disease onset and progression
- Microglial IL1A drives neuroinflammation in SOD1G93A and other ALS mouse models
IL1A binding to IL1R1 triggers the canonical NF-κB pathway:
- MyD88 recruited to the IL1R1 intracellular domain via TIR domain interactions
- IRAK4 and IRAK1/2 recruited, forming the Myddosome signaling complex
- TRAF6 activates TAK1, which phosphorylates the IKK complex (IKKα, IKKβ, IKKγ)
- IκBα is phosphorylated and degraded by the proteasome, releasing NF-κB (p65/p50 heterodimer)
- NF-κB translocates to nucleus, inducing inflammatory gene transcription
Target genes include:
- Pro-inflammatory cytokines: IL6, TNF-α, IL1B itself (creating amplification loop)
- Chemokines: CCL2 (MCP-1), CXCL1 (GRO-α), CXCL8 (IL-8) (recruiting immune cells)
- Adhesion molecules: VCAM1, ICAM1 (facilitating leukocyte extravasation)
- Enzymes: COX2 (producing prostaglandins), iNOS (producing NO)
IL1A directly activates the NLRP3 inflammasome in primed cells:
- IL1A-induced ROS production provides signal 1 for NLRP3 priming (NF-κB-dependent pro-caspase-1 and pro-IL1B transcription)
- IL1A primes cells for enhanced NLRP3 response to secondary triggers (ATP, nigericin, αSyn oligomers)
- This creates a feed-forward loop: IL1A → NF-κB → NLRP3 priming → caspase-1 activation → IL1B release → more IL1A
IL1A has profound effects on neuroglial cells:
- Microglia: Converts resting microglia to the pro-inflammatory M1 phenotype through STAT1 and NF-κB activation; increases phagocytosis initially but impairs debris clearance over time
- Astrocytes: Induces reactive astrogliosis (A1 phenotype) with enhanced inflammatory profile; disrupts astrocyte support of neuronal function and glutamate uptake
- Oligodendrocytes: Direct toxicity through activation of apoptotic pathways; impairs differentiation of oligodendrocyte precursor cells
IL1A intersects with multiple pathways central to neurodegeneration:
- Protein aggregation: NF-κB activation upregulates APP and BACE1, increasing Aβ production; IL1A promotes tau phosphorylation through GSK3β
- Mitochondrial dysfunction: IL1A impairs mitochondrial respiration and promotes mitochondrial permeability transition
- Oxidative stress: IL1A induces iNOS and NADPH oxidase, generating reactive oxygen and nitrogen species
- Autophagy dysregulation: IL1A inhibits autophagic flux, reducing clearance of protein aggregates
| Drug |
Mechanism |
Status in Neurodegeneration |
| Anakinra (Kineret) |
IL1R1 blockade (recombinant IL-1RA) |
Phase 2 in AD/PD - well tolerated, modest cognitive effects |
| Canakinumab (Ilaris) |
Anti-IL-1β monoclonal |
CANTOS trial showed reduced neurodegeneration biomarkers |
| Rilonacept (Arcalyst) |
IL-1 trap (IL1R1+IL1R2 ectodomain fusion) |
Preclinical for neuroprotection |
¶ Challenges and Considerations
- IL-1A has both pro-inflammatory and homeostatic functions; complete blockade may impair beneficial CNS immune surveillance
- The blood-brain barrier limits access of large biologics; new approaches needed (nanobodies, small molecules)
- Timing is critical: early blockade may prevent pathology, late intervention may have limited benefit
- Biomarker-guided patient selection may be needed (IL1A-high patients most likely to benefit)
- NCT04735770: Anakinra in Alzheimer's disease (Phase 2, 12-month treatment)
- NCT04059874: Canakinumab cognitive outcomes in post-MI patients (subgroup analysis for neurodegeneration biomarkers)
- NCT04163107: IL-1 blockade in Parkinson's disease (observational study)
- NCT03806456: Anakinra in ALS (Phase 2, safety and biomarker study)